ABOUT US
Neutron Therapy Corporation GmbH is part of a private innovative companies international network (Switzerland, EU, UAE, Israel, Canada, Russia) which leads the development of various scientific and technological projects, including specialized solutions in nuclear medicine, production of advanced materials, isotopes Boron-10, Zirconium-96, Ytterbium-176, Actinium-227 and others for nuclear medicine, nuclear energy, fundamental science, R&D.
NTC was founded in 2019 for the development and marketing of the compact medical source of neutrons for neutron therapy and radiopharmaceutical production
ABOUT US
Neutron Therapy Corporation GmbH is part of a private innovative companies international network (Switzerland, EU, UAE, Israel, Canada, Russia) which leads the development of various scientific and technological projects, including specialized solutions in nuclear medicine, production of advanced materials, isotopes Boron-10, Zirconium-96, Ytterbium-176, Actinium-227 and others for nuclear medicine, nuclear energy, fundamental science, R&D.
NTC was founded in 2019 for the development and marketing of the compact medical source of neutrons for neutron therapy and radiopharmaceutical production
THE NEUTRON THERAPY METHODOLOGY
The neutron therapy methodology for treatment of specific cancers has been known and used for years and has been sufficiently studied. Specialists in the field consider this methodology to be very effective in the treatment of oncological diseases. This therapy effective in the treatment of various types of cancer, but some types of cancer, such as deep-seated and resistant tumors, can be treated effectively only with this neutron therapy (30% of all known cancer). Neutron therapy offers higher relative biologic effectiveness compared with proton or photon therapy.
Today neutron therapy is generally carried out in two ways:
1
At the location of research nuclear reactors that can produce and emit neutron beam
2
Using proton accelerators to produce the secondary neutron beam
However, the use of research nuclear reactors and proton accelerators have limitations such as:
Having large dimensions, and therefore impractical to be accommodated in an operating clinic
High cost of irradiation
"MARS" FOR NEUTRON THERAPY
Neutron Therapy Corporation has developed a conceptual design for a unique source of neutrons “MARS” with the following characteristics:
Long life cycle - over 20 years
Extra-low power (1-10 kW)
Small size
(3.5 m х 2.0 m х 3.5 m)
A simple on/off control
Can be installed inside a clinic
Because of the small size and low cost of therapy session "MARS" can be widely used all over the world for neutron therapy of cancer.Moreover, "MARS" produces 2 neutron beams both for boron neutron-capture therapy (BNCT) and for fast neutron therapy (FNT).
"MARS" FOR NEUTRON THERAPHY
NTC has developed a conceptual design for a unique source of neutrons “MARS” with the following characteristics:
Long life cycle - over 20 years
Extra-low power (1-10 kW)
Small size (3.5 m х 2.0 m х 3.5 m)
A simple on/off control
Can be installed inside the clinic
Because of the small size and low cost of therapy session "MARS" can be widely used all over the world for neutron therapy of cancer.Moreover, "MARS" produces 2 neutron beams both for boron neutron-capture therapy (BNCT) and for fast neutron therapy (FNT).
"MARS" PROJECT FROM AN ECONOMIC POINT OF VIEW
The demand for neutron therapy just in Europe is more than
60 000
patients per year and the number grows for 5 000–8 000 patients yearly
To date one neutron therapy session on the available research nuclear reactors or proton accelerators is about
€ 75 000
per session (one session = a course of treatment)
Thus, the main obstacle to the wide application of neutron therapy in medical practice is the high cost of session and large dimensions of research nuclear reactors and proton accelerators.
Thus, the market situation indicates the need for a compact, inexpensive neutron source for neutron therapy, which can be located in a medical facility.
OFFER FOR INVESTORS
The development of two business models is proposed:
Build-Own-Operate
Build-Own-Operate
This model provides for the construction of a network of neutron therapy centers based on the "MARS" unit. The potential net profit of each center will be about € 40 million per year on average, according to experts, about 30 such centers are required only for the EU.
Build and Sell
Build and Sell
This model implies receiving orders, manufacturing and supplying "MARS" units to existing clinics. The net profit from sale one
"MARS" unit will amount to about € 40 million. According to experts, 30 "MARS" units are required only for the EU.'
The cost for pilot "MARS" unit is estimated at € 30 million, mass produced - € 10 million.
Investors are invited to take part in the pilot project.
TEAM AND ACHIEVEMENTS
To date, the company has developed a conceptual project, obtained patents in the following countries: Russia, the European Union, the USA, Canada, Japan, Vietnam, India, Indonesia, China, South Korea, Malaysia, Singapore, Thailand, etc.
The team of NTC comprises well-known scientists, designers, engineers with years-long experience of building nuclear reactors; in fact, several team members built and commissioned the BN-600 fast neutron reactor (active). In addition to engineers and designers there are about 20 doctors of science and 5 professors specializing in nuclear physics, neutron physics, nuclear and radiation safety, etc.
CONTACTS
To request a video conference or for other enquiries, please, contact us: mars@neutrontherapy.org
Aegeristrasse 5, 6300 Zug, ZG, Switzerland
Политика конфиденциальности
Редактируемый текст
Данный сайт использует Cookie
Редактируемый текст